Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M81,774Revenue $M8,264Net Margin (%)11.7Altman Z-Score2.2
Enterprise Value $M103,407EPS $2.7Operating Margin %26.0Piotroski F-Score6
P/E(ttm)87.2Beneish M-Score-2.5Pre-tax Margin (%)14.4Higher ROA y-yY
Price/Book12.710-y EBITDA Growth Rate %10.5Quick Ratio4.9Cash flow > EarningsY
Price/Sales9.65-y EBITDA Growth Rate %55.9Current Ratio5.2Lower Leverage y-yN
Price/Free Cash Flow48.6y-y EBITDA Growth Rate %136ROA % (ttm)3.4Higher Current Ratio y-yY
Dividend Yield %--PEG1.6ROE % (ttm)18.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M342ROIC % (ttm)7.3Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXBill Ackman 2015-03-31 Buy 25.84%$142.83 - $204.69
($177.4)
$ 238.7735%New holding19,473,933
VRXWallace Weitz 2015-03-31 Reduce-1.84%$142.83 - $204.69
($177.4)
$ 238.7735%Reduce 33.46%917,261
VRXSteve Mandel 2015-03-31 Reduce-1.62%$142.83 - $204.69
($177.4)
$ 238.7735%Reduce 32.50%5,569,460
VRXJohn Paulson 2015-03-31 Add1.6%$142.83 - $204.69
($177.4)
$ 238.7735%Add 293.70%2,050,000
VRXGlenn Greenberg 2015-03-31 Reduce-1.24%$142.83 - $204.69
($177.4)
$ 238.7735%Reduce 4.07%5,877,016
VRXGeorge Soros 2015-03-31 Sold Out -0.95%$142.83 - $204.69
($177.4)
$ 238.7735%Sold Out0
VRXChris Davis 2015-03-31 Reduce-0.74%$142.83 - $204.69
($177.4)
$ 238.7735%Reduce 46.50%1,877,040
VRXLou Simpson 2015-03-31 Add0.71%$142.83 - $204.69
($177.4)
$ 238.7735%Add 5.81%1,898,540
VRXJoel Greenblatt 2015-03-31 Reduce-0.26%$142.83 - $204.69
($177.4)
$ 238.7735%Reduce 77.83%65,531
VRXRuane Cunniff 2015-03-31 Reduce-0.18%$142.83 - $204.69
($177.4)
$ 238.7735%Reduce 0.71%34,089,378
VRXPrivate Capital 2015-03-31 Add0.06%$142.83 - $204.69
($177.4)
$ 238.7735%Add 0.86%295,320
VRXGlenn Greenberg 2014-12-31 Reduce-2.23%$113.56 - $146.39
($134.66)
$ 238.7777%Reduce 6.98%6,126,609
VRXSteve Mandel 2014-12-31 Reduce-1.39%$113.56 - $146.39
($134.66)
$ 238.7777%Reduce 24.90%8,250,886
VRXWallace Weitz 2014-12-31 Reduce-1.2%$113.56 - $146.39
($134.41)
$ 238.7778%Reduce 18.50%1,378,606
VRXJoel Greenblatt 2014-12-31 Buy 0.34%$113.56 - $146.39
($134.66)
$ 238.7777%New holding295,632
VRXLou Simpson 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 238.7777%Reduce 1.19%1,794,227
VRXRuane Cunniff 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 238.7777%Reduce 0.47%34,331,973
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 238.77101%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 238.77101%Add 12.40%1,815,916
VRXWallace Weitz 2014-09-30 Add0.54%$106.73 - $130.26
($118.9)
$ 238.77101%Add 9.05%1,691,525
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Whitaker Anne ClemDirector 2015-05-26Buy7,500$234.671.75view
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-05-04Sell90,938$222.547.29view
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-03-02Sell90,939$200.0119.38view
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.4848.78view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.0670.48view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.7363.84view
Stevenson, Katharine BerghuisDirector 2014-12-03Buy1,500$145.7363.84view
UBBEN JEFFREY W 2014-11-24Buy210,000$142.2567.85view
Farmer Ronald HaroldDirector 2014-11-24Buy1,000$163.9545.64view
Farmer, RonDirector 2014-11-24Buy1,000$163.9545.64view

Press Releases about VRX :

    Quarterly/Annual Reports about VRX:

    News about VRX:

    Articles On GuruFocus.com
    Thursday’s Pre-Market Insights: GoPro Inc (GPRO), NeoStem Inc (NBS), Valeant Pharmaceuticals Intl May 28 2015 
    Bill Ackman Adds Two Positions to Portfolio in 1QFY15 May 19 2015 
    John Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba May 16 2015 
    Locust Wood Capital Bet on Top Performer Valeant Pharmaceuticals May 14 2015 
    Weekly Insider Sells Highlight: VRX, HCA, GPRO, GD May 11 2015 
    Bill Ackman's Ira Sohn Presentation – Long Jarden, Platform Specialty Products and Valeant May 06 2015 
    Submit Questions for Upcoming Q&A With Value Investor Wally Weitz Apr 27 2015 
    Weitz Value Fund First Quarter 2015 Commentary Apr 20 2015 
    The Top Guru-Held Canadian Stocks Apr 11 2015 
    Valeant Finally Bags Salix for $11 Billion Apr 06 2015 

    More From Other Websites
    Build a Billionaire Portfolio With These 20 Stocks May 29 2015
    Valeant, Actavis Neck And Neck With Bowel Disorder Drugs May 28 2015
    Valeant Pharmaceuticals Gets FDA Nod for Xifaxan for IBS-D - Analyst Blog May 28 2015
    Could Avago Become The Valeant Pharmaceuticals Of The Semiconductor Sector? May 28 2015
    Actavis, Valeant Up On Bowel-Disease Drug Approvals May 28 2015
    Valeant Now Worth More Than Toronto-Dominion as Drugmakers Surge May 28 2015
    After Salix acquisition, Valeant receives FDA approval for IBS-D drug May 27 2015
    Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel... May 27 2015
    Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel... May 27 2015
    Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel... May 27 2015
    FDA approves Actavis, Valeant drugs for irritable bowel syndrome May 27 2015
    Actavis PLC (ACT), Pfizer Inc. (PFE) Among the Most Popular Healthcare Stocks of Billionaire... May 27 2015
    Some Hedge Fund ETFs Love Healthcare Stocks May 27 2015
    5 most popular health-care stocks among hedge funds May 26 2015
    5 Most Popular Healthcare Stocks Among Hedge Funds May 26 2015
    5 Drugs That Could Be Summer Blockbusters May 26 2015
    Overheard: ‘Bubble’ Talk Won’t Slow Health Care Merger Pace May 25 2015
    Overheard May 25 2015
    'Bubble' Talk Won't Slow Health Care Merger Pace May 25 2015
    Pharming and Cytobioteck Announce Distribution Agreement for Ruconest May 25 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK